Market revenue in 2023 | USD 26.0 million |
Market revenue in 2030 | USD 44.5 million |
Growth rate | 7.9% (CAGR from 2023 to 2030) |
Largest segment | Small molecule |
Fastest growing segment | Large Molecule |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Small Molecule, Large Molecule |
Key market players worldwide | IQVIA Holdings Inc, JSR Corp, Taconic Biosciences, Evotec SE, Janvier Labs, Charles River Laboratories International Inc, Icon PLC, Labcorp Holdings Inc, PAREXEL, GemPharmatech, PsychoGenics, Biocytogen, SMO-Group |
Small molecule was the largest segment with a revenue share of 63.85% in 2024. Horizon Databook has segmented the Thailand in vivo cro market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.
Thailand has a well-developed healthcare infrastructure and a robust regulatory framework to ensure ethical conduct and patient safety in preclinical studies. The country has implemented several guidelines and standards that align with international best practices, providing confidence to sponsors and regulatory bodies.
Furthermore, the country’s diverse population and extensive range of animal models make it an ideal location for conducting in vivo studies. The availability of various genetic backgrounds and disease models allows researchers to simulate human conditions accurately, enhancing the relevance and reliability of their research outcomes.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account